PL3411473T3 - Mezenchymalne komórki macierzyste nasilające aktywność antynowotworową immunoterapii - Google Patents

Mezenchymalne komórki macierzyste nasilające aktywność antynowotworową immunoterapii

Info

Publication number: PL3411473T3
Authority: PL; Poland
Prior art keywords: immunotherapy; stem cells; mesenchymal stem; cancer activity; cells enhancing
Prior art date: 2016-04-01

Application number

PL17715658T

Other languages

English (en)

Inventor

Felix Hermann

Christine Günther

Ulf GEUMANN

Original Assignee

JunctuCell Biomed Manufacturing GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-01

Filing date

2017-03-31

Publication date

2021-05-04

2017-03-31 Application filed by JunctuCell Biomed Manufacturing GmbH filed Critical JunctuCell Biomed Manufacturing GmbH

2021-05-04 Publication of PL3411473T3 publication Critical patent/PL3411473T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4264—Cancer antigens from embryonic or fetal origin
- A61K40/4266—Carcinoembryonic antigen [CEA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/54—Pancreas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Developmental Biology & Embryology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Hematology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Virology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Mycology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL17715658T 2016-04-01 2017-03-31 Mezenchymalne komórki macierzyste nasilające aktywność antynowotworową immunoterapii PL3411473T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP16163557		2016-04-01
EP16176185		2016-06-24
PCT/EP2017/057679 WO2017167959A1 (en)	2016-04-01	2017-03-31	Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy
EP17715658.5A EP3411473B1 (en)	2016-04-01	2017-03-31	Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy

Publications (1)

Publication Number	Publication Date
PL3411473T3 true PL3411473T3 (pl)	2021-05-04

Family

ID=58489308

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17715658T PL3411473T3 (pl)	2016-04-01	2017-03-31	Mezenchymalne komórki macierzyste nasilające aktywność antynowotworową immunoterapii

Country Status (10)

Country	Link
US (2)	US20190030152A1 (pl)
EP (2)	EP3730607A1 (pl)
JP (1)	JP6971986B2 (pl)
KR (1)	KR20190003456A (pl)
CN (1)	CN108884440A (pl)
AU (2)	AU2017242899A1 (pl)
CA (1)	CA3008352A1 (pl)
ES (1)	ES2823162T3 (pl)
PL (1)	PL3411473T3 (pl)
WO (1)	WO2017167959A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20190133254A (ko) *	2017-04-07	2019-12-02	시나타 세라퓨틱스 엘티디	키메라 항원 수용체 (car) t 세포 요법의 부작용을 치료하는 방법
CA3066799A1 (en) *	2017-06-16	2018-12-20	Cynata Therapeutics Limited	Method for treating a side effect of immunotherapy
US12016882B2 (en)	2017-11-22	2024-06-25	The Brigham And Women's Hospital, Inc.	Method of treating glioblastoma multiforme
ES3051182T3 (en)	2019-01-23	2025-12-26	Miltenyi Biotec Bv & Co Kg	A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
AU2021217373A1 (en) *	2020-02-05	2022-08-04	Neoimmunetech, Inc.	Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
WO2022155585A2 (en) *	2021-01-15	2022-07-21	City Of Hope	Methods of preparing and expanding type i innate lymphoid cells and therapeutic uses thereof
CN112980888B (zh) *	2021-02-22	2023-04-14	广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院）	分泌il-6抗体/cd20抗体的间充质干细胞、构建方法及其应用
WO2023076670A1 (en) *	2021-11-01	2023-05-04	MAM Holdings of West Florida, L.L.C.	Mesenchymal stem cells for the prevention and targeted treatment of cancer and other disorders
EP4180049A1 (en) *	2021-11-16	2023-05-17	Ostravska univerzita	Therapeutic composition for cancer treatment
US20230218671A1 (en) *	2022-01-10	2023-07-13	Creative Medical Technologies, Inc.	Chimeric antigen receptor regenerative gamma delta t cells
CA3253035A1 (en) *	2022-06-09	2023-12-14	Kite Pharma, Inc.	METHODS FOR PREPARING LYMPHOCYTES FOR CELL THERAPY
CN115463155B (zh) *	2022-11-01	2023-05-23	卡瑞济(北京)生命科技有限公司	间充质干细胞的用途
WO2025225578A1 (ja) *	2024-04-25	2025-10-30	ロート製薬株式会社	癌治療剤
WO2025264721A1 (en) *	2024-06-17	2025-12-26	Immorta Bio, Inc.	Enhancement of regenerative activity by inactivation of senescent cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1757703A3 (en)	2005-08-24	2007-12-05	Medizinische Hochschule Hannover	Self-inactivating retroviral vector
KR101022401B1 (ko) *	2005-09-29	2011-03-15	아주대학교산학협력단	자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
ES2507507T3 (es)	2007-05-24	2014-10-15	Apceth Gmbh & Co. Kg	Células madre mesenquimales CD34 negativas modificadas genéticamente para el tratamiento de tumores
US8557578B2 (en)	2009-12-23	2013-10-15	Apceth Gmbh & Co. Kg	Expansion medium for CD34-negative stem cells
CN102641298B (zh) *	2012-05-15	2014-03-05	祁岩超	一种预防和治疗肿瘤的效应细胞组合及其制备方法
US10022402B2 (en) *	2012-12-03	2018-07-17	Subhadra Dravida	Allogenic mesendritic vector for ovarian cancer
EP3446708A1 (en) *	2012-12-24	2019-02-27	Cell Ideas Pty Ltd.	Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US20170239297A1 (en) *	2014-08-18	2017-08-24	Apceth Gmbh & Co. Kg	Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
TW201619133A (zh) *	2014-08-21	2016-06-01	裘拉德製藥私人有限公司	新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物

2017
- 2017-03-31 JP JP2018534792A patent/JP6971986B2/ja active Active
- 2017-03-31 AU AU2017242899A patent/AU2017242899A1/en not_active Abandoned
- 2017-03-31 CA CA3008352A patent/CA3008352A1/en active Pending
- 2017-03-31 CN CN201780016729.XA patent/CN108884440A/zh active Pending
- 2017-03-31 WO PCT/EP2017/057679 patent/WO2017167959A1/en not_active Ceased
- 2017-03-31 ES ES17715658T patent/ES2823162T3/es active Active
- 2017-03-31 EP EP20177392.6A patent/EP3730607A1/en not_active Withdrawn
- 2017-03-31 EP EP17715658.5A patent/EP3411473B1/en active Active
- 2017-03-31 PL PL17715658T patent/PL3411473T3/pl unknown
- 2017-03-31 US US16/081,010 patent/US20190030152A1/en not_active Abandoned
- 2017-03-31 KR KR1020187021245A patent/KR20190003456A/ko not_active Withdrawn
2022
- 2022-10-25 US US18/049,408 patent/US20230063829A1/en active Pending
2023
- 2023-09-27 AU AU2023237078A patent/AU2023237078A1/en active Pending

Also Published As

Publication number	Publication date
AU2017242899A1 (en)	2018-07-05
WO2017167959A1 (en)	2017-10-05
CA3008352A1 (en)	2017-10-05
KR20190003456A (ko)	2019-01-09
US20230063829A1 (en)	2023-03-02
ES2823162T3 (es)	2021-05-06
EP3411473B1 (en)	2020-07-08
CN108884440A (zh)	2018-11-23
US20190030152A1 (en)	2019-01-31
JP6971986B2 (ja)	2021-11-24
AU2023237078A1 (en)	2023-10-12
EP3730607A1 (en)	2020-10-28
EP3411473A1 (en)	2018-12-12
JP2019509715A (ja)	2019-04-11

Publication	Publication Date	Title
IL250689A0 (en)	2017-04-30	Resetting pluripotent stem cells
IL262458A (en)	2018-12-31	Methods for selectively modulating the activity of distinct subtypes of cells
EP3510145A4 (en)	2020-03-25	IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS
EP3624810A4 (en)	2021-02-17	NANO-ACTIVATED IMMUNOTHERAPY FOR CANCER DISEASES
IL257009A (en)	2018-03-29	Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
DK3253865T3 (da)	2022-08-15	Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller
DK3523423T3 (da)	2024-09-02	Fremgangsmåder til målrettet differentiering af pluripotente stamceller til hla homozygote immunceller
DK3455344T3 (da)	2025-01-06	Hæmatopoietiske stam-/Progenitorceller
HUE053101T2 (hu)	2021-06-28	Javított T-sejt-készítmények
DK3134095T3 (da)	2020-06-29	Forbedrede fremgangsmåder til fremstilling af adoptive celleterapier
LT3556777T (lt)	2021-04-12	Daugiaspecifiniai antikūno konstruktai
BR112017009540A2 (pt)	2018-06-19	biorreator usando macroalgas
GEAP202114450A (en)	2021-07-26	Anti-tigit antibodies
LT3628680T (lt)	2021-11-25	Komplemento aktyvumo moduliavimas
DK3164414T3 (da)	2020-07-06	Antistoffer for IL-15
EP3221446C0 (en)	2024-08-21	IN VITRO PRODUCTION OF EXPANDED POTENTIAL STEM CELLS
DK3577219T3 (da)	2023-11-13	Alfa-amylase-varianter
DK3157504T3 (da)	2019-11-04	Stamcellestimulerende sammensætninger
HUE053760T2 (hu)	2021-07-28	SUV39h1-deficiens immunsejtek
EP3037812C0 (en)	2024-05-01	ENZYME ELECTRODE
KR20180085018A (ko)	2018-07-25	조혈 줄기/전구 세포의 확장된 집단의 용도
DK3766582T3 (da)	2022-06-20	Cellekultur
BR112016019822A2 (pt)	2017-08-15	Determinação enzimática de hba1c
MX377774B (es)	2025-03-11	Formulaciones de proteinas.
DK3167052T3 (da)	2020-02-10	P450-bm3-varianter med forbedret aktivitet